Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant

NCT03657342 is registered in ClinicalTrials.gov with Zambon SpA as lead sponsor.

NCT NCT03657342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03657342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Single Lung Transplant
Lead sponsor
Zambon SpA
Phase
Phase 3
Overall status
Completed
Start date
March 26, 2019
Completion date
April 16, 2024
Enrollment
62 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

bronchiolitis obliterans, chronic lung allograft dysfunction, chronic rejection of lung transplant, lung transplant failure and rejection, lung transplant rejection, lung transplant; complications